Table 4.
Baseline clinical and pathological information of the JCAD high- and low-expression groups in the present study cohort
| Clinical and pathological characteristics | Total (%) N=111 |
JCAD expression | P value | |
|---|---|---|---|---|
| Low (%) N=55 |
High (%) N=56 |
|||
Age (years,
 ±s)
|
50.1±9.1 | 52.5±9.4 | 0.159 | |
| Age (years) | 0.218 | |||
| < 50 | 48 (43.2) | 27 (49.1) | 21 (37.5) | |
| ≥ 50 | 63 (56.8) | 28 (50.9) | 35 (62.5) | |
| T | 0.380 | |||
| T1 | 32 (28.8) | 20 (36.4) | 12 (21.4) | |
| T2 | 53 (47.7) | 23 (41.8) | 30 (53.6) | |
| T3 | 15 (13.5) | 7 (12.7) | 8 (14.3) | |
| T4 | 11 (9.9) | 5 (9.1) | 6 (10.7) | |
| N | 0.552 | |||
| Negative | 38 (34.2) | 19 (34.5) | 19 (33.9) | |
| Positive | 73 (65.8) | 36 (65.5) | 37 (66.1) | |
| M | 0.005 | |||
| M0 | 77 (69.4) | 45 (81.8) | 32 (57.1) | |
| M1 | 34 (30.6) | 10 (18.2) | 24 (42.9) | |
| Stage | 0.037 | |||
| I | 26 (23.4) | 15 (27.3) | 11 (19.6) | |
| II | 36 (32.4) | 20 (36.4) | 16 (28.6) | |
| III | 15 (13.5) | 10 (18.2) | 5 (8.9) | |
| IV | 34 (30.6) | 10 (18.2) | 24 (42.9) | |
| ER | 0.509 | |||
| Negative | 53 (47.7) | 28 (50.9) | 25 (44.6) | |
| Positive | 58 (52.3) | 27 (49.1) | 31 (55.4) | |
| PR | 0.785 | |||
| Negative | 64 (57.7) | 31 (56.4) | 33 (58.9) | |
| Positive | 47 (42.3) | 24 (43.6) | 23 (41.1) | |
| HER2 | 0.379 | |||
| Negative | 64 (57.7) | 34 (61.8) | 30 (53.6) | |
| Positive | 47 (42.3) | 21 (38.2) | 26 (46.4) | |
| Immunohistochemical type | 0.371 | |||
| Luminal | 58 (52.3) | 27 (49.1) | 31 (55.4) | |
| HER2 positive | 27 (24.3) | 12 (21.8) | 15 (26.8) | |
| TNBC | 26 (23.4) | 16 (29.1) | 10 (17.9) | |